Abstract: There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, for example abnormal RAS activity caused by a mutation in RAS, including cancers with a mutated RAS.
Type:
Application
Filed:
October 14, 2022
Publication date:
December 12, 2024
Applicant:
GENETOLEAD INC.
Inventors:
Luc FARMER, Steven LAPLANTE, Yann AYOTTE, Sacha Thierry LARDA, Saba ALAPOUR, Simon WOO, David BENDAHAN, Maria DENK, Majid FARAHANI, Mustapha IDDIR